DK1505066T3 - Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre - Google Patents

Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre

Info

Publication number
DK1505066T3
DK1505066T3 DK02724323T DK02724323T DK1505066T3 DK 1505066 T3 DK1505066 T3 DK 1505066T3 DK 02724323 T DK02724323 T DK 02724323T DK 02724323 T DK02724323 T DK 02724323T DK 1505066 T3 DK1505066 T3 DK 1505066T3
Authority
DK
Denmark
Prior art keywords
alpha
polymorph
ethoxyethyl
benzimidazole
piperidinyl
Prior art date
Application number
DK02724323T
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Mori Gonzalo Canal
Fuente Haydee Blanco
De Pablo Maria Luisa Lucero
Royo Victor Rubio
Martin Maravillas Bordell
Pestana Ramon Mosquera
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1505066(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Application granted granted Critical
Publication of DK1505066T3 publication Critical patent/DK1505066T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02724323T 2002-04-19 2002-04-19 Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre DK1505066T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (1)

Publication Number Publication Date
DK1505066T3 true DK1505066T3 (da) 2007-03-19

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02724323T DK1505066T3 (da) 2002-04-19 2002-04-19 Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre

Country Status (31)

Country Link
US (2) US7612095B2 (da)
EP (1) EP1505066B1 (da)
JP (1) JP5142448B2 (da)
KR (1) KR100673140B1 (da)
CN (1) CN1290843C (da)
AR (1) AR039423A1 (da)
AT (1) ATE347550T1 (da)
AU (1) AU2002255017B2 (da)
BG (1) BG66302B1 (da)
BR (1) BRPI0215703B8 (da)
CA (1) CA2484460C (da)
CY (2) CY1107564T1 (da)
CZ (1) CZ305162B6 (da)
DE (1) DE60216641T2 (da)
DK (1) DK1505066T3 (da)
ES (1) ES2278018T3 (da)
HK (1) HK1072772A1 (da)
HR (1) HRP20041048B1 (da)
HU (1) HU230032B1 (da)
IL (1) IL164645A (da)
MX (1) MXPA04010313A (da)
NO (1) NO329327B1 (da)
NZ (1) NZ536551A (da)
PA (1) PA8571201A1 (da)
PE (1) PE20040086A1 (da)
PT (1) PT1505066E (da)
SI (1) SI1505066T1 (da)
SK (1) SK288052B6 (da)
UA (1) UA76866C2 (da)
UY (1) UY27762A1 (da)
WO (1) WO2003089425A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
WO2013001731A1 (ja) * 2011-06-30 2013-01-03 パナソニック株式会社 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
CA2993134A1 (en) * 2015-07-24 2017-02-02 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF
EP3453384B1 (en) 2017-09-07 2020-05-27 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine
PL3641735T3 (pl) 2017-12-18 2021-09-06 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Kompozycja farmaceutyczna tabletki zawierająca bilastynę w postaci 3 i rozpuszczalny w wodzie wypełniacz
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
CN111727035B (zh) 2018-01-18 2024-05-28 费斯制药股份有限公司 包含比拉斯汀、β-环糊精和至少一种胶凝剂的眼用组合物
WO2022135863A1 (en) 2020-12-23 2022-06-30 Biohorm, S.L. A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
RU2001130883A (ru) * 1999-04-16 2004-03-20 Др. Редди`З Лабораториз Лимитед (In) Новые полиморфные формы антидиабетического средства, способ их получения и содержащие их фармацевтические композиции
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt

Also Published As

Publication number Publication date
CN1290843C (zh) 2006-12-20
UA76866C2 (uk) 2006-09-15
CY2013015I1 (el) 2015-08-05
US7612095B2 (en) 2009-11-03
CY1107564T1 (el) 2013-03-13
BRPI0215703B1 (pt) 2017-06-27
CA2484460C (en) 2009-09-29
JP5142448B2 (ja) 2013-02-13
CZ20041122A3 (cs) 2005-03-16
MXPA04010313A (es) 2005-06-08
IL164645A0 (en) 2005-12-18
HRP20041048A2 (en) 2005-02-28
SK50202004A3 (sk) 2005-05-05
UY27762A1 (es) 2003-09-30
CA2484460A1 (en) 2003-10-30
US20050203141A1 (en) 2005-09-15
ES2278018T3 (es) 2007-08-01
AU2002255017A1 (en) 2003-11-03
BRPI0215703B8 (pt) 2021-05-25
DE60216641D1 (de) 2007-01-18
PT1505066E (pt) 2007-03-30
AU2002255017B2 (en) 2008-11-13
CN1628112A (zh) 2005-06-15
ATE347550T1 (de) 2006-12-15
BR0215703A (pt) 2005-02-01
NO329327B1 (no) 2010-09-27
KR100673140B1 (ko) 2007-01-22
HRP20041048A9 (hr) 2013-01-31
HU230032B1 (hu) 2015-05-28
BG66302B1 (bg) 2013-03-29
PA8571201A1 (es) 2003-12-10
WO2003089425A1 (es) 2003-10-30
EP1505066A1 (en) 2005-02-09
NZ536551A (en) 2006-08-31
HRP20041048B1 (hr) 2013-04-30
CY2013015I2 (el) 2015-08-05
IL164645A (en) 2010-11-30
EP1505066B1 (en) 2006-12-06
HK1072772A1 (en) 2005-09-09
US20100004285A1 (en) 2010-01-07
BG108941A (en) 2005-12-30
KR20050005448A (ko) 2005-01-13
SK288052B6 (sk) 2013-03-01
CZ305162B6 (cs) 2015-05-27
NO20044999L (no) 2005-01-14
SI1505066T1 (sl) 2007-04-30
HUP0500241A2 (hu) 2005-06-28
PE20040086A1 (es) 2004-04-27
DE60216641T2 (de) 2007-09-27
AR039423A1 (es) 2005-02-16
JP2005529120A (ja) 2005-09-29

Similar Documents

Publication Publication Date Title
DK1505066T3 (da) Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
CY2020002I2 (el) Μυκητοκτονος συνθεση η οποια περιεχει ενα παραγωγο οξινου αμιδιου
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
IL238911A0 (en) Polymorphic form of 3-(4-amino-1-oxo-3,1 dihydro-isoindol-2-yl)-piperidine-6,2-dione
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE433968T1 (de) Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
ATE401893T1 (de) Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
ATE463486T1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ATE314808T1 (de) Neues 2-pyridylethylbenzamid-derivat
HK1080843A1 (en) (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DK1692242T3 (da) Viskoelastisk syre
DE60322857D1 (de) Neues alpha-amino-n-(diaminophosphinyl)lactamderivat
ATE383329T1 (de) Biaryloxymethylarenecarbonsäure
DK1753760T3 (da) 4-hydroxy-4-methyl-piperidin-1-carboxylsyre-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amid
DK1542970T3 (da) Pyrrolidinderivater som MAOB-inhibitorer
DE60302137D1 (de) Piperidinderivate
DK1506316T3 (da) Fremgangsmåde til forbedring af effektiviteten ved husdyrproduktion
ATE477803T1 (de) Metabolit von quetiapine
IS7585A (is) Ný piperadín efnasambönd
DE602005010986D1 (de) Neue pyrrolidin-3,4-dicarbonsäureamidderivate
DK2024354T3 (da) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidin-derivater til behandling af gastrointestinale sygdomme 1
NO20043457L (no) 3-(imidazolyl)-2-alkoksypropansyrer som TAFIA inhibitorer